Griffith Parkinson's Disease Research Network

Share Griffith Parkinson's Disease Research Network on Facebook Share Griffith Parkinson's Disease Research Network on Twitter Share Griffith Parkinson's Disease Research Network on Linkedin Email Griffith Parkinson's Disease Research Network link

About Us

We are the Griffith Parkinson's Disease Research Network, a collective of researchers dedicated to advancing the understanding of Parkinson's disease. Our primary objectives include exploring the molecular mechanisms underlying Parkinson's disease, identifying potential drug targets, developing innovative early diagnostic techniques, and identifying new molecules that can target essential biological pathways for therapeutic applications.

Our Highlights

  1. We have established a new knockout mouse model and a series of behavioural tests that are being used to understand the role of a new potential target for Parkinson's disease.
  2. We have established several patient-derived induced pluripotent stem cell (iPSC) lines, which carry an interesting mutation that is associated with Parkinson's disease through genetic linkage study of a big family with heritable Parkinson's disease. We are differentiating these iPSCs into dopaminergic neurons to investigate how the mutation affects neuron functions.
  3. We are developing effective compounds from natural products that can improve the mitochondrial functions of neurons. These compounds have the potential as drug leads for treating Parkinson’s disease.
  4. We are developing new diagnostic method using blood and saliva samples from patients.
  5. We have organised three successful annual Parkinson’s Disease Symposiums and will have the fourth one in Nov 2023. The symposoium has been attracting Parkinson’s disease researchers from various research institutes in Brisbane, including UQ, QUT, and QIMR, and is becoming a platform for researchers in this field to share ideas and get inspirations.

About Us

We are the Griffith Parkinson's Disease Research Network, a collective of researchers dedicated to advancing the understanding of Parkinson's disease. Our primary objectives include exploring the molecular mechanisms underlying Parkinson's disease, identifying potential drug targets, developing innovative early diagnostic techniques, and identifying new molecules that can target essential biological pathways for therapeutic applications.

Our Highlights

  1. We have established a new knockout mouse model and a series of behavioural tests that are being used to understand the role of a new potential target for Parkinson's disease.
  2. We have established several patient-derived induced pluripotent stem cell (iPSC) lines, which carry an interesting mutation that is associated with Parkinson's disease through genetic linkage study of a big family with heritable Parkinson's disease. We are differentiating these iPSCs into dopaminergic neurons to investigate how the mutation affects neuron functions.
  3. We are developing effective compounds from natural products that can improve the mitochondrial functions of neurons. These compounds have the potential as drug leads for treating Parkinson’s disease.
  4. We are developing new diagnostic method using blood and saliva samples from patients.
  5. We have organised three successful annual Parkinson’s Disease Symposiums and will have the fourth one in Nov 2023. The symposoium has been attracting Parkinson’s disease researchers from various research institutes in Brisbane, including UQ, QUT, and QIMR, and is becoming a platform for researchers in this field to share ideas and get inspirations.
  • A Critical New Target for Parkinson's Disease

    Share A Critical New Target for Parkinson's Disease on Facebook Share A Critical New Target for Parkinson's Disease on Twitter Share A Critical New Target for Parkinson's Disease on Linkedin Email A Critical New Target for Parkinson's Disease link

    Linlin Ma and her collaborators are investigating a novel mutation in the KCNJ15 gene, which is genetically linked to Parkinson’s disease (PD) in multiple generations of an Australian family with Parkinson’s but is absent in a large cohort of healthy controls. Their initial findings indicate that the KCNJ15 mutation from the Australian family is a loss-of-function mutation. Supported by funding from the Michael J Fox Foundation, the Ma group has developed iPSC lines derived from the family members who have this mutation. They will convert these iPSCs into dopaminergic neurons in vitro in order to assess what effect this mutation has on neurons. In parallel, they are characterising a KCNJ15 knockout mouse model, focusing on motor phenotypes, pathology, and inflammation. KCNJ15 gene encodes an ion channel protein that is very druggable, so successful results from this project might highlight a new therapeutic target for Parkinson’s, along with readily available tools to develop and test therapeutics.

Page last updated: 16 Jan 2024, 01:34 PM